Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Phreesia, Inc. and its officers or directors [1] Financial Performance - On May 30, 2024, Phreesia announced its financial results for Q1 of fiscal year 2025, updating its revenue outlook to a range of $416 million to $426 million, down from a previous range of $424 million to $434 million [3] - The updated revenue outlook reflects the accelerated wind-down of a clearinghouse client relationship and assumes no additional revenue from potential future acquisitions before January 31, 2025 [3] - Following the announcement, Phreesia's stock price dropped by $2.39 per share, or 11.22%, closing at $18.92 per share on May 31, 2024 [3]

Group 1 - The stock of Phreesia (PHR) has experienced a significant downtrend, declining 18.3% over the past four weeks, but is now in oversold territory, indicating a potential for a turnaround [1][5] - The Relative Strength Index (RSI) for PHR is currently at 26.52, suggesting that the heavy selling pressure may be exhausting itself and a price reversal could be imminent [5][6] - Analysts have raised their earnings estimates for PHR, with a consensus EPS estimate increase of 8.7% over the last 30 days, which typically correlates with price appreciation [6][7] Group 2 - PHR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [7]

PART I — FINANCIAL INFORMATION [Item 1. Financial Statements](index=7&type=section&id=Item%201.%20Financial%20Statements) Phreesia, Inc. reported **$101.2 million** in revenue and a **$19.7 million** net loss for Q1 FY2025, significantly improving from the prior year with reduced cash used in operations Consolidated Balance Sheet Highlights (Unaudited) | Account | April 30, 2024 (in thousands) | January 31, 2024 (in thousands) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $79,527 | $87,520 | | Total current assets | $190,901 | $195,684 | | Total Assets | $372,086 | $370,326 | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $108,282 | $110,119 | | Total Liabilities | $119,344 | $118,877 | | Total Stockholders' Equity | $252,742 | $251,449 | Consolidated Statement of Operations Highlights (Unaudited) | Metric | Three months ended April 30, 2024 (in thousands) | Three months ended April 30, 2023 (in thousands) | | :--- | :--- | :--- | | Total revenues | $101,217 | $83,845 | | Operating loss | $(19,420) | $(37,901) | | Net loss | $(19,722) | $(37,531) | | Net loss per share, basic and diluted | $(0.35) | $(0.70) | Consolidated Statement of Cash Flows Highlights (Unaudited) | Cash Flow Activity | Three months ended April 30, 2024 (in thousands) | Three months ended April 30, 2023 (in thousands) | | :--- | :--- | :--- | | Net cash used in operating activities | $(721) | $(13,659) | | Net cash used in investing activities | $(5,446) | $(6,079) | | Net cash used in financing activities | $(1,825) | $(7,178) | | Net decrease in cash and cash equivalents | $(7,993) | $(26,916) | [Notes to Unaudited Consolidated Financial Statements](index=13&type=section&id=Notes%20to%20Unaudited%20Consolidated%20Financial%20Statements) The notes detail accounting policies, revenue sources, and financial statement composition, confirming sufficient liquidity and the establishment of a new Indian subsidiary - Management believes the company's cash and cash equivalents of **$79.5 million**, along with cash from operations and available borrowing capacity, are sufficient to fund operations for at least the next 12 months[38](index=38&type=chunk) - The company generates revenue from three primary sources: subscription and related services, payment processing fees, and network solutions for life sciences and payer clients[66](index=66&type=chunk) Stock-Based Compensation Expense by Type | Award Type | Three months ended April 30, 2024 (in thousands) | Three months ended April 30, 2023 (in thousands) | | :--- | :--- | :--- | | RSUs | $11,323 | $12,899 | | PSUs | $2,804 | $1,644 | | Liability awards | $2,697 | $2,525 | | ESPP | $364 | $370 | | Stock options | $0 | $37 | | **Total** | **$17,188** | **$17,475** | - During the quarter, the company established and commenced operations of a subsidiary in India, Phreesia India Private Limited, to support various business functions, replacing services previously provided by a third-party[131](index=131&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=29&type=section&id=Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management reported a **21%** revenue increase to **$101.2 million** and positive Adjusted EBITDA of **$4.1 million**, despite impacts from recent cybersecurity incidents and a slight decline in revenue per client [Financial Highlights and Recent Developments](index=29&type=section&id=Financial%20Highlights%20and%20Recent%20Developments) Q1 FY2025 saw **21%** revenue growth to **$101.2 million**, a narrowed net loss, and positive Adjusted EBITDA, alongside impacts from cybersecurity incidents at Change Healthcare, Ascension Health, and Phreesia's ConnectOnCall service Q1 FY2025 Financial Highlights | Metric | Three months ended April 30, 2024 | Three months ended April 30, 2023 | | :--- | :--- | :--- | | Total revenue | $101.2 million | $83.8 million | | Net loss | $(19.7) million | $(37.5) million | | Adjusted EBITDA | $4.1 million | $(13.8) million | | Net cash used in operating activities | $(0.7) million | $(13.7) million | | Free cash flow | $(6.2) million | $(19.7) million | - The cyberattack on Change Healthcare accelerated the wind-down of a relationship with a clearinghouse client, reducing payment processing revenue by approximately **$1.7 million** in the first quarter of fiscal 2025[146](index=146&type=chunk) - On May 12, 2024, the company's ConnectOnCall service experienced a service disruption due to a cybercriminal gaining access; the incident is not expected to have a material impact on overall business operations as it is separate from the main patient intake platform[152](index=152&type=chunk)[154](index=154&type=chunk)[155](index=155&type=chunk) [Key Metrics](index=32&type=section&id=Key%20Metrics) Key performance indicators show **23%** growth in average healthcare services clients to **4,065**, but a slight decline in revenue per AHSC, while patient payment volume increased **15%** to **$1.166 billion** Key Performance Metrics | Metric | Three months ended April 30, 2024 | Three months ended April 30, 2023 | | :--- | :--- | :--- | | Average number of healthcare services clients (AHSCs) | 4,065 | 3,309 | | Healthcare services revenue per AHSC | $18,155 | $18,779 | | Total revenue per AHSC | $24,900 | $25,338 | | Patient payment volume (in millions) | $1,166 | $1,016 | - The decline in revenue per AHSC was primarily driven by AHSC growth significantly outpacing the growth in payment processing volume and revenue[160](index=160&type=chunk) [Results of Operations](index=33&type=section&id=Results%20of%20Operations) Total revenue increased **21%** to **$101.2 million**, driven by growth across all segments, while improved cost control led to a significant reduction in operating loss Revenue by Segment (in thousands) | Revenue Stream | Q1 FY2025 | Q1 FY2024 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Subscription and related services | $46,742 | $37,887 | $8,855 | 23% | | Payment processing fees | $27,060 | $24,253 | $2,807 | 12% | | Network solutions | $27,415 | $21,705 | $5,710 | 26% | | **Total revenue** | **$101,217** | **$83,845** | **$17,372** | **21%** | - Sales and marketing expense decreased by **$5.4 million (14%)** year-over-year, primarily due to lower employee salary and benefits costs, travel expenses, and the full run-off of expenses from winding down Medicare Advantage lead generation activities[178](index=178&type=chunk)[179](index=179&type=chunk) - Research and development expense increased by **$2.4 million (9%)** due to higher employee salary and benefits costs and increased software costs[180](index=180&type=chunk) [Non-GAAP Financial Measures](index=38&type=section&id=Non-GAAP%20Financial%20Measures) Adjusted EBITDA significantly improved to **$4.1 million** from a **$13.8 million** loss, and free cash flow improved to negative **$6.2 million**, reflecting higher revenue and lower operating expenses Reconciliation of Net Loss to Adjusted EBITDA (in thousands) | Line Item | Three months ended April 30, 2024 | Three months ended April 30, 2023 | | :--- | :--- | :--- | | Net loss | $(19,722) | $(37,531) | | Interest income, net | $(239) | $(718) | | Provision for income taxes | $510 | $306 | | Depreciation and amortization | $6,673 | $6,990 | | Stock-based compensation expense | $16,840 | $17,138 | | Other expense, net | $31 | $42 | | **Adjusted EBITDA** | **$4,093** | **$(13,773)** | Reconciliation of Net Cash Used in Operating Activities to Free Cash Flow (in thousands) | Line Item | Three months ended April 30, 2024 | Three months ended April 30, 2023 | | :--- | :--- | :--- | | Net cash used in operating activities | $(721) | $(13,659) | | Less: Capitalized internal-use software | $(4,570) | $(4,732) | | Less: Purchases of property and equipment | $(876) | $(1,347) | | **Free cash flow** | **$(6,167)** | **$(19,738)** | [Liquidity and Capital Resources](index=39&type=section&id=Liquidity%20and%20Capital%20Resources) As of April 30, 2024, Phreesia had **$79.5 million** in cash and access to a **$50 million** credit facility, with significantly improved net cash used in operating activities - As of April 30, 2024, the company had cash and cash equivalents of **$79.5 million** and access to a **$50 million** senior secured asset-based revolving credit facility with Capital One, which matures in December 2028[195](index=195&type=chunk)[198](index=198&type=chunk) Summary of Cash Flows (in thousands) | Activity | Three months ended April 30, 2024 | Three months ended April 30, 2023 | | :--- | :--- | :--- | | Net cash used in operating activities | $(721) | $(13,659) | | Net cash used in investing activities | $(5,446) | $(6,079) | | Net cash used in financing activities | $(1,825) | $(7,178) | | **Net decrease in cash and cash equivalents** | **$(7,993)** | **$(26,916)** | - The significant improvement in net cash used in operating activities was primarily driven by an increase in cash received from customers due to higher revenues[207](index=207&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=42&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces minimal interest rate risk but is exposed to foreign currency exchange risk from operations in Canada and India, though a 1% change is not expected to be material - The company's primary market risks are interest rate risk and foreign currency exchange risk[218](index=218&type=chunk) - Interest rate risk is low due to the short maturity of cash equivalents and no outstanding debt on the Capital One Credit Facility as of April 30, 2024[219](index=219&type=chunk)[220](index=220&type=chunk) - The company is subject to foreign currency exchange risk from operations in Canada and India, particularly related to the Canadian Dollar and Indian Rupee, with approximately **89%** of expenses denominated in USD for the three months ended April 30, 2024[221](index=221&type=chunk) [Controls and Procedures](index=42&type=section&id=Item%204.%20Controls%20and%20Procedures) As of April 30, 2024, the CEO and CFO concluded that disclosure controls and procedures were effective, with no material changes to internal control over financial reporting during the quarter - Management, including the CEO and CFO, concluded that as of April 30, 2024, the company's disclosure controls and procedures were effective at the reasonable assurance level[224](index=224&type=chunk) - There were no material changes in the company's internal control over financial reporting during the quarter ended April 30, 2024[225](index=225&type=chunk) PART II — OTHER INFORMATION [Legal Proceedings](index=43&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any legal proceedings expected to have a material adverse effect on its business or financial condition - The company is not presently a party to any legal proceedings that would have a material adverse effect on its business[228](index=228&type=chunk) [Risk Factors](index=43&type=section&id=Item%201A.%20Risk%20Factors) The company faces diverse risks including managing rapid growth, intense competition, cybersecurity threats, regulatory compliance (HIPAA, data privacy), intellectual property protection, and heavy reliance on third-party vendors and partners [Risks relating to our business and industry](index=43&type=section&id=Risks%20relating%20to%20our%20business%20and%20industry) Business risks include managing rapid growth, intense competition, a history of net losses, cybersecurity threats, and the challenges of a fully remote operational model - The company's rapid growth strains operations and employees, and failure to manage this growth could hinder revenue increases and business strategy implementation[230](index=230&type=chunk) - The company faces intense competition from a fragmented market, including EHR and PM systems, which could harm business and operating results[234](index=234&type=chunk) - The company has a history of net losses, including **$19.7 million** for the three months ended April 30, 2024, and may not achieve profitability in the future as it continues to invest in growth[242](index=242&type=chunk) - Cybersecurity incidents, such as the recent one affecting ConnectOnCall and those impacting partners like Change Healthcare, pose significant risks of economic loss, reputational damage, and legal liability[247](index=247&type=chunk) [Risks relating to our payments business](index=54&type=section&id=Risks%20relating%20to%20our%20payments%20business) Risks to the payments business include platform limitations, failure to integrate new technologies, increased card network fees, and non-compliance with network rules, which could lead to fines or termination of payment facilitator status - The payments platform, generating **27%** of total revenue, is a core business component, and any disruption or failure to grow it could materially harm the business[291](index=291&type=chunk) - Increases in card network fees (interchange fees) could reduce earnings if the company is unable to pass these costs on to clients due to competitive pressure[293](index=293&type=chunk) - Non-compliance with card network rules could lead to fines, suspension, or termination of the company's payment facilitator status, adversely affecting the business[294](index=294&type=chunk) [Risks relating to our data and intellectual property](index=55&type=section&id=Risks%20relating%20to%20our%20data%20and%20intellectual%20property) Risks include inadequate protection of proprietary technology, potential litigation from open-source software use or third-party IP infringement claims, and reliance on licensed third-party data - The business depends on proprietary technology, and inadequate intellectual property protection may prevent the company from safeguarding its technology and brand[298](index=298&type=chunk) - Use of open-source software could lead to litigation or require the company to disclose proprietary source code, harming its competitive position[301](index=301&type=chunk) - The company could face legal proceedings from third parties alleging infringement of their intellectual property rights, which could be uncertain, costly, and divert management resources[307](index=307&type=chunk) [Risks relating to laws and regulations applicable to our industry](index=59&type=section&id=Risks%20relating%20to%20laws%20and%20regulations%20applicable%20to%20our%20industry) The company faces extensive regulatory risks from complex federal and state laws, including HIPAA, evolving data privacy laws (CCPA, GDPR), TCPA for messaging, and an uncertain healthcare regulatory framework - The company, as a 'Business Associate' under HIPAA, is subject to numerous federal and state laws governing protected health information, with non-compliance potentially leading to significant fines and penalties[317](index=317&type=chunk)[319](index=319&type=chunk) - Evolving data privacy laws in the U.S. (like CCPA) and internationally (like GDPR) create complex compliance issues, potentially requiring business practice changes and incurring substantial costs[324](index=324&type=chunk)[327](index=327&type=chunk) - The company's calling and text messaging services are subject to the Telephone Consumer Protection Act (TCPA), posing a risk of significant liability from individual or class-action lawsuits[353](index=353&type=chunk)[355](index=355&type=chunk) - The healthcare regulatory framework is uncertain and evolving, with potential changes to the ACA and new rules on interoperability and 'information blocking' that could impact the business[343](index=343&type=chunk)[344](index=344&type=chunk) [Risks relating to our dependence on third parties](index=67&type=section&id=Risks%20relating%20to%20our%20dependence%20on%20third%20parties) The company heavily relies on third-party contractors, vendors, and partners for critical services, creating risks related to service quality, security, supply chain disruptions, and business continuity, as highlighted by recent cyberattacks on partners - The company relies on third-party contractors for critical services like software development and cloud hosting, including international locations like India and Ukraine, exposing it to geopolitical and operational risks[360](index=360&type=chunk) - The company relies on a sole supplier for the manufacturing of its PhreesiaPads and Arrivals Kiosks, creating a significant supply chain risk[369](index=369&type=chunk) - Service delivery is dependent on internet infrastructure and third-party data centers, where any failure, such as the recent cyberattack on partner Change Healthcare, could disrupt services and negatively impact the business[372](index=372&type=chunk)[374](index=374&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=76&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered securities were sold during the quarter ended April 30, 2024, that had not been previously reported on a Form 8-K - No unregistered securities were sold during the quarter that had not been previously reported[399](index=399&type=chunk) [Other Information](index=76&type=section&id=Item%205.%20Other%20Information) Three company executives, including the CEO and CFO, adopted Rule 10b5-1 trading plans in April 2024 for the potential sale of common stock shares - On April 18, 2024, Amy Beth VanDuyn, SVP of Human Resources, adopted a Rule 10b5-1 Trading Plan for the potential sale of up to **25,447** shares of common stock, expiring December 31, 2024[402](index=402&type=chunk) - On April 19, 2024, CEO Chaim Indig adopted a Rule 10b5-1 Trading Plan for the potential exercise of stock options and sale of up to **100,000** shares, expiring April 17, 2026[403](index=403&type=chunk) - On April 19, 2024, CFO Balaji Gandhi adopted a Rule 10b5-1 Trading Plan for the sale of up to **43,362** shares plus additional shares from his bonus, expiring March 14, 2025[404](index=404&type=chunk) [Exhibits](index=77&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including corporate governance documents, officer certifications, and XBRL data files - The exhibits filed with this report include corporate governance documents, CEO and CFO certifications (Sections 302 and 906), and XBRL data files[405](index=405&type=chunk)

Financial Data and Key Metrics - Q1 revenue increased by 21% to $101.2 million [16] - Adjusted EBITDA turned positive for the first time in three years, reaching $4.1 million [16] - Average Healthcare Services clients increased by 103 from the prior quarter, with total revenue per AHSC at $24,900 [16] - Operating cash flow for Q1 was just under breakeven at negative $721,000 [20] - Cash position stood at $80 million as of April 30, 2024 [20] Business Line Data and Key Metrics - Payment processing revenue was negatively impacted by $1.7 million due to the accelerated wind-down of a clearinghouse client relationship [17] - The clearinghouse client relationship represented approximately $8 million in annual revenue, impacting fiscal 2025 results [18] - Network solutions are expected to be the primary driver of revenue growth per client, with payments and other products lagging behind [44] Market Data and Key Metrics - The company updated its fiscal 2025 revenue outlook to a range of $416 million to $426 million, reflecting an $8 million reduction due to the clearinghouse client wind-down [19] - Adjusted EBITDA outlook for fiscal 2025 was increased to a range of $21 million to $26 million, reflecting improved operating leverage [20] Company Strategy and Industry Competition - The company is focusing on shorter payback investments to accelerate profitability, driven by internal discounted cash flow analyses and shareholder feedback [22] - Investments in cybersecurity have been ramping up, with continued expectations for increased spending in this area [28] - The company is prioritizing growth while also being more aggressive in driving profitability, considering factors like cost of capital and interest rates [37] Management Commentary on Operating Environment and Future Outlook - Management highlighted the importance of the first quarter as a milestone in the company's journey back to profitability [13] - The company is well-positioned to start generating free cash flow in the second half of fiscal 2025 [21] - The healthcare provider market remains receptive to the company's solutions, with a general view that continuous investment in technology is necessary to drive efficiency and better margins [40] Other Important Information - The company has no borrowings on its revolving credit facility, providing financial flexibility over the next few years [21] - Gross margins reached over 80% in Q1, the highest level in recent history, with expectations to sustain this level through the year [57] Q&A Session Summary Question: Cybersecurity Investments and Financial Impact from Ascension Attack - The company has been increasing investments in cybersecurity for years, with plans to continue ramping up spending in this area [28] - The Ascension cyberattack did not have a significant financial impact on the company, but the industry-wide challenges are unprecedented [26][27] Question: Clearinghouse Client Wind-Down and Risks in the Model - The wind-down of the clearinghouse client relationship was mutually agreed upon due to the client's desire to consolidate vendors, and the process was accelerated by the Change Healthcare cyberattack [32] - No other significant risks related to client contracts or relationships with Change Healthcare were identified [33] Question: Drivers Behind EBITDA Increase and Margin Progression - The strong start to the year and focus on returning to profitability have reinforced the company's commitment to driving profitability more aggressively [37] - The company expects to continue seeing solid operating leverage, contributing to improved EBITDA margins [20] Question: Provider End Market and Phreesia Solution Deployment - The provider end market remains receptive to the company's solutions, with a focus on technology investments to drive efficiency and better margins [40] - The company has continued to win accounts and grow its market share despite industry challenges [40] Question: Strategy for Accelerating Revenue per Client Growth - Network solutions are expected to be the primary driver of revenue growth per client, with payments and other products playing a secondary role [44] Question: MediFind Appointment Requests and New Provider Targeting - The MediFind appointment request product has been well-received, with early traction showing promise for driving value across specialty providers [46] - The company expects MediFind to be a significant driver of network solutions revenue growth in the future [50] Question: Health of Payments Business and Gross Margins - Excluding the impact of the clearinghouse client wind-down, the payments business has been consistent with historical performance [56] - Gross margins reached over 80% in Q1, with expectations to sustain this level through the year [57] Question: Mix and Quality of Healthcare Services Clients - The company continues to add a diverse mix of healthcare services clients, with a focus on shorter payback periods and higher conversion rates [59] Question: Phreesia Launch and Margin Impact - The launch of Phreesia has not had a significant financial impact, as the expenses were already running through the P&L [61] Question: Take Rate Degradation in Payments and Pricing Strategy - The company is comfortable with current pricing levels, with take rates expected to fluctuate around 2.8% in the coming quarters [65] Question: Shorter Payback Investments and Client Upselling - The company is optimizing for profitability and quicker payback periods, with a focus on upselling additional products to clients [67][68]

For the quarter ended April 2024, Phreesia (PHR) reported revenue of $101.22 million, up 20.7% over the same period last year. EPS came in at -$0.35, compared to -$0.70 in the year-ago quarter. The reported revenue represents a surprise of +0.20% over the Zacks Consensus Estimate of $101.01 million. With the consensus EPS estimate being -$0.51, the EPS surprise was +31.37%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

Phreesia (PHR) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.70 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 31.37%. A quarter ago, it was expected that this developer of health care software would post a loss of $0.58 per share when it actually produced a loss of $0.56, delivering a surprise of 3.45%. Over the last four quarters, the c ...

Exhibit 99.1 Phreesia Announces First Quarter Fiscal 2025 Results ALL-REMOTE COMPANY/WILMINGTON, D.E., May 30, 2024 – Phreesia, Inc. (NYSE: PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal first quarter ended April 30, 2024. "I am tremendously proud of our team's commitment to our growth and profitability objectives." said CEO and Co- Founder Chaim Indig. 1 Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q1 Fiscal Year 2025 Sta ...

The average prediction of analysts places 'Revenus- Network solutions' at $26.04 million. The estimate indicates a change of +20% from the prior-year quarter. The collective assessment of analysts points to an estimated 'Revenus- Payment processing fees' of $27.92 million. The estimate indicates a change of +15.1% from the prior-year quarter. Wall Street analysts expect Phreesia (PHR) to post quarterly loss of $0.51 per share in its upcoming report, which indicates a year-over-year increase of 27.1%. Revenu ...

andreswd Summary Following my coverage of Phreesia (NYSE:PHR), for which I reiterated a buy rating given that fundamentals remained sound and that PHR could continue to see pricing tailwinds ahead, this post is to provide an update on my thoughts on the business and stock. I reiterate my buy rating for PHR as I see the business continuing to grow revenue at 20+% and the adjusted EBITDA margin inflecting upwards as the business scales. The new product rolled out to target post-script engagements should also ...

Phreesia (PHR) reported $95.01 million in revenue for the quarter ended January 2024, representing a year-over-year increase of 24%. EPS of -$0.56 for the same period compares to -$0.72 a year ago.The reported revenue represents a surprise of +2.01% over the Zacks Consensus Estimate of $93.13 million. With the consensus EPS estimate being -$0.58, the EPS surprise was +3.45%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...